| Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation E Zamagni, F Patriarca, C Nanni, B Zannetti, E Englaro, A Pezzi, ... Blood, The Journal of the American Society of Hematology 118 (23), 5989-5995, 2011 | 609 | 2011 |
| Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with … M Cavo, L Pantani, MT Petrucci, F Patriarca, E Zamagni, D Donnarumma, ... Blood, The Journal of the American Society of Hematology 120 (1), 9-19, 2012 | 395* | 2012 |
| Combination of International Scoring System 3, high lactate dehydrogenase, and t (4; 14) and/or del (17p) identifies patients with multiple myeloma (MM) treated with front-line … P Moreau, M Cavo, P Sonneveld, L Rosinol, M Attal, A Pezzi, ... Journal of clinical oncology 32 (20), 2173-2180, 2014 | 199 | 2014 |
| PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma E Zamagni, C Nanni, K Mancuso, P Tacchetti, A Pezzi, L Pantani, ... Clinical Cancer Research 21 (19), 4384-4390, 2015 | 187 | 2015 |
| 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease E Zamagni, C Nanni, F Gay, A Pezzi, F Patriarca, M Bellò, I Rambaldi, ... Leukemia 30 (2), 417-422, 2016 | 144 | 2016 |
| Italian cancer figures, report 2012: cancer in children and adolescents AIRTUM Working Group, AIEOP Working Group Epidemiologia e prevenzione 37 (1 Suppl 1), 1-225, 2013 | 139* | 2013 |
| Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk L Roncucci, E Mora, F Mariani, S Bursi, A Pezzi, G Rossi, M Pedroni, ... Cancer Epidemiology Biomarkers & Prevention 17 (9), 2291-2297, 2008 | 132 | 2008 |
| Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network … M Cavo, A Palumbo, S Zweegman, MA Dimopoulos, R Hajek, L Pantani, ... Journal of Clinical Oncology 34 (15_suppl), 8000-8000, 2016 | 89 | 2016 |
| The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients C Nanni, E Zamagni, M Celli, P Caroli, V Ambrosini, P Tacchetti, A Brioli, ... Clinical nuclear medicine 38 (2), e74-e79, 2013 | 88 | 2013 |
| Cyclooxygenase-2 and hypoxia-inducible factor-1α protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis F Mariani, P Sena, L Marzona, M Riccio, R Fano, P Manni, C Di Gregorio, ... Cancer Letters 279 (2), 221-229, 2009 | 85 | 2009 |
| Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in … M Cavo, L Pantani, A Pezzi, MT Petrucci, F Patriarca, F Di Raimondo, ... Leukemia 29 (12), 2429-2431, 2015 | 84 | 2015 |
| Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients AIRTUM Working Group Epidemiologia e prevenzione 34 (5-6 Suppl 2), 1-188, 2010 | 66 | 2010 |
| Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment BA Zannetti, E Zamagni, M Santostefano, LB De Sanctis, P Tacchetti, ... American Journal of Hematology 90 (7), 647-652, 2015 | 59 | 2015 |
| Bortezomib‐and thalidomide‐induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study P Tacchetti, C Terragna, M Galli, E Zamagni, MT Petrucci, A Pezzi, ... American journal of hematology 89 (12), 1085-1091, 2014 | 59 | 2014 |
| Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells V Salvestrini, S Orecchioni, G Talarico, F Reggiani, C Mazzetti, F Bertolini, ... Oncotarget 8 (4), 5895, 2017 | 56 | 2017 |
| Epidemiology of colorectal cancer: the 21-year experience of a specialised registry M Ponz de Leon, G Rossi, C Di Gregorio, C De Gaetani, F Rossi, G Ponti, ... Internal and Emergency Medicine 2, 269-279, 2007 | 55 | 2007 |
| Italian cancer figures, report 2011: Survival of cancer patients in Italy AIRTUM Working Group Epidemiologia e prevenzione 35 (5-6 Suppl 3), 1-200, 2011 | 50 | 2011 |
| The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) C Terragna, D Remondini, M Martello, E Zamagni, L Pantani, F Patriarca, ... Oncotarget 7 (9), 9666, 2016 | 38 | 2016 |
| Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation A Brioli, G Perrone, F Patriarca, A Pezzi, F Nobile, F Ballerini, MR Motta, ... Bone Marrow Transplantation 50 (5), 673-678, 2015 | 35 | 2015 |
| Relative role of APC and MUTYH mutations in the pathogenesis of familial adenomatous polyposis A Pezzi, L Roncucci, P Benatti, R Sassatelli, L Varesco, C Di Gregorio, ... Scandinavian journal of gastroenterology 44 (9), 1092-1100, 2009 | 31 | 2009 |
